Accendra Health (ACH) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
14 May, 2026Opening remarks and agenda
Meeting called to order with directors and executive officers present; shareholders welcomed and meeting procedures outlined.
Inspector of Election and meeting secretary introduced; rules of conduct and Q&A process explained.
Shareholder proposals
Four proposals presented: election of six directors, ratification of KPMG LLP as auditor, advisory vote on executive compensation, and approval of amended 2023 Omnibus Incentive Plan.
All nominees for director positions listed and confirmed; no additional nominations accepted.
Overview of voting outcomes
Quorum confirmed with 81.29% of shares represented; polls opened and closed for voting.
All four proposals received majority approval, including director elections, auditor ratification, executive compensation, and incentive plan.
Final voting results to be filed on Form 8-K within four business days.
Latest events from Accendra Health
- Q2 2026 featured a 10.1% revenue drop, major debt reduction, and CEO succession plans.ACH
Q2 2026 - Plans to raise up to $200 million via a flexible shelf offering for general corporate purposes.ACH
Registration filing - Q1 2026 revenue fell 6.8% to $627.8M, with a $1.5B balance sheet reset to boost liquidity.ACH
Q1 2026 - Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.ACH
Proxy filing - Shareholders to vote on directors, auditor, executive pay, and expanded equity plan amid strategic transformation.ACH
Proxy filing - 2026 guidance projects $2.55–$2.65B revenue, $335–$355M EBITDA, and strong cash flow.ACH
Q4 2025 - Q3 revenue up 5% to $2.7B, driven by Patient Direct and $198M debt reduction.ACH
Q3 2024 - Q2 revenue up 4–4.2% to $2.67–$2.7B; Rotech deal announced; 2024 outlook reaffirmed.ACH
Q2 2024 - $1.36B Rotech deal expands Patient Direct, targets $5B revenue, $50M synergies by year three.ACH
M&A Announcement